Patients: ChromSeq for Whole Genome Sequencing

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Washington University School of Medicine, Saint Louis, MO
Whole Genome Sequencing+1 More
ChromoSeq - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).

Eligible Conditions

  • Whole Genome Sequencing
  • Myelodysplastic Syndromes

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Whole Genome Sequencing

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: Through 1 month after generation of ChromoSeq for all patients enrolled (estimated to be 16 months)

Month 16
Stakeholder perceptions of ChromoSeq
Month 15
Proportion of failed ChromoSeq assays
Rate of assay success on first attempt between ChromoSeq and conventional cytogenetics as measured by total number of copy number alterations identified
Rate of assay success on first attempt between ChromoSeq and conventional cytogenetics as measured by total number of recurrent structural variants identified

Trial Safety

Safety Progress

1 of 3

Other trials for Whole Genome Sequencing

Trial Design

2 Treatment Groups

Stakeholders (Treating Physicians)
1 of 2
Patients: ChromSeq
1 of 2
Active Control
Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: Patients: ChromSeq · No Placebo Group · N/A

Patients: ChromSeq
Device
Experimental Group · 1 Intervention: ChromoSeq · Intervention Types: Device
Stakeholders (Treating Physicians)NoIntervention Group · 1 Intervention: Stakeholders (Treating Physicians) · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through 1 month after generation of chromoseq for all patients enrolled (estimated to be 16 months)
Closest Location: Washington University School of Medicine · Saint Louis, MO
Photo of washington university school of medicine  1Photo of washington university school of medicine  2Photo of washington university school of medicine  3
2004First Recorded Clinical Trial
2 TrialsResearching Whole Genome Sequencing
1465 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years of age.
You are able to understand and willing to sign an IRB approved informed consent document.
You are a physician who treats individuals with hematologic malignancies.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.